BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CEO Mark A. Sirgo sold 65,405 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the sale, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at $4,150,470.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

BioDelivery Sciences International, Inc. (BDSI) opened at 2.80 on Friday. The company has a market cap of $155.33 million, a P/E ratio of 100.00 and a beta of 1.04. BioDelivery Sciences International, Inc. has a 12-month low of $1.50 and a 12-month high of $3.60. The stock’s 50 day moving average is $3.08 and its 200-day moving average is $2.47.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.04). The business had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.45 million. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. The business’s revenue for the quarter was up 74.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.31) EPS. Analysts predict that BioDelivery Sciences International, Inc. will post $0.12 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Mark A. Sirgo Sells 65,405 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/24/mark-a-sirgo-sells-65405-shares-of-biodelivery-sciences-international-inc-bdsi-stock.html.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Valley National Advisers Inc. raised its position in BioDelivery Sciences International by 59.0% during the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after acquiring an additional 14,000 shares in the last quarter. KCG Holdings Inc. raised its position in BioDelivery Sciences International by 469.9% during the first quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock worth $210,000 after acquiring an additional 91,297 shares in the last quarter. Grandeur Peak Global Advisors LLC raised its position in BioDelivery Sciences International by 5.9% during the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after acquiring an additional 56,550 shares in the last quarter. NEXT Financial Group Inc raised its position in BioDelivery Sciences International by 9.3% during the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Blair William & Co. IL raised its position in BioDelivery Sciences International by 37.6% during the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock worth $1,386,000 after acquiring an additional 189,484 shares in the last quarter. 41.43% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on the stock. ValuEngine downgraded shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $4.50 price target on shares of BioDelivery Sciences International in a research report on Monday, August 14th. Finally, Janney Montgomery Scott upped their price target on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average price target of $4.21.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.